Search our Innovation Portfolio

Our project aims to reduce the time taken from diagnosis of a brain tumour to the beginning of treatment. We will achieve our aim by developing a new care process to allow key steps to happen in parallel.

This will be supported by our digital platform which enables data sharing across different institutions. We have already been able to reduce the time from first diagnosis to specialist discussion, and plan to extend this work to cover the entire period up to treatment. We will also develop a standard way of sharing data between individual hospital systems. By studying data collected and carrying out workshops, we will develop a 'toolkit' that will enable our findings to be applied to other cancers

GPs in England currently refer 2.5 million patients a year for possible cancer diagnosis. Over 9 in every 10 of them do not have cancer but undergo multiple expensive, time consuming and stressful diagnostic tests, affecting patient lives and using funds that could be used elsewhere. The PinPoint test was designed to reduce the number of patients needing these tests, thereby reducing patient anxiety, pressure on doctors and increasing diagnostic capacity. Working with NHS doctors, PinPoint designed the test using machine learning which takes a range of blood measurements to produce a single number that tells doctors a patient’s chance of having cancer which they can then use to more effectively stratify, triage, prioritise and safety net 2WW patients.

Visit Pinpoint Data Science website

The PinPoint Test is a decision support tool for clinicians. A stratification, prioritisation, safety netting and triage test for NHS cancer patients using data from a single blood draw, running on existing NHS IT/laboratory testing systems under NHS control.

qXR, a class II CE approved medical device, detects and localises 20+ abnormalities on a CXR including the presence of lung nodules. qXR is intended to support consultant radiologists and reporting radiographers in clinical decision making. It is an automated chest x-ray AI algorithm to improve efficiency, accuracy and turnaround time (TAT) in reporting CXRs. QXR is deployed in more than 30+ countries for multiple disease applications including Tuberculosis, COVID-19 and Lung cancer. With two US patents for the product and several validation studies published in leading journals like The Lancet, qXR has proven to be accurately identifying the abnormalities in the lung, in a few minutes.